Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 01, 2025 07:00 ET | Source: Arvinas Inc.

Arvinas to Present Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson’s Disease and Movement Disorders®

NEW HAVEN, Conn., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
April 15, 2025 03:00 ET | Source: AKAMPION

1ST Biotherapeutics Joins The Michael J. Fox Foundation’s LITE Program to Advance LRRK2-Based Parkinson’s Disease Research

Focus on the discovery of next-generation LRRK2 inhibitors to unlock novel biological mechanisms of action and advance new treatment options YONGIN, South Korea, April 15, 2025 – 1ST Biotherapeutics,...
February 27, 2020 16:30 ET | Source: Denali Therapeutics Inc.

Denali Therapeutics Reports Full Year 2019 Financial Results and Business Highlights

SOUTH SAN FRANCISCO, Calif., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to...
December 10, 2018 09:00 ET | Source: Denali Therapeutics Inc.

Denali Therapeutics Announces First Patient Dosed in Phase 1b Study of DNL201 for Parkinson’s Disease

Phase 1b study includes Parkinson’s disease patients with and without a genetic LRRK2 mutation SOUTH SAN FRANCISCO, Calif., Dec. 10, 2018 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ:...